Compare Stocks → FW: 234x Gain (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:QPTNASDAQ:TRIL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeQPTAdvisorShares Q Portfolio Blended Allocation ETF$19.10+0.1%$19.10$18.63▼$27.54$1.91MN/A1,912 shs19,400 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceQPTAdvisorShares Q Portfolio Blended Allocation ETF0.00%0.00%0.00%0.00%0.00%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceQPTAdvisorShares Q Portfolio Blended Allocation ETF0.00N/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/ATRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/A0.00∞N/AN/AN/AN/AN/ATRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthQPTAdvisorShares Q Portfolio Blended Allocation ETF$0.080.42%N/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/ATRILTrillium TherapeuticsN/A19.8219.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipQPTAdvisorShares Q Portfolio Blended Allocation ETFN/ATRILTrillium Therapeutics87.15%Insider OwnershipCompanyInsider OwnershipQPTAdvisorShares Q Portfolio Blended Allocation ETFN/ATRILTrillium Therapeutics9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableQPTAdvisorShares Q Portfolio Blended Allocation ETFN/A100,000N/ANot OptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableQPT and TRIL HeadlinesSourceHeadlineCachet Bicycle shakes off COVIDbaytoday.ca - February 25 at 12:23 PMRejuvenate your look with a trip to Fourth Avenue Medical Aestheticschch.com - January 30 at 5:32 PMTTI apprehends motorists for illegal removal of clamps, hunt for four others underwaybulawayo24.com - January 30 at 5:32 PMBridgeBio raises $1.25bn, and other biotech financingspharmaphorum.com - January 19 at 7:18 AMRatio Therapeutics Raises $50M in Series B Financingprecisionmedicineonline.com - January 17 at 1:39 PMLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.combusinesswire.com - November 10 at 1:22 PMMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 8 at 1:30 AMThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast perioduk.finance.yahoo.com - July 31 at 9:03 AMRatio Therapeutics unveils new research and development facilitybiopharma-reporter.com - May 15 at 10:33 AMWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'msn.com - April 26 at 12:18 AMLeukemia Therapeutics Global Market Report 2023uk.finance.yahoo.com - April 4 at 10:35 AMRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merckfinance.yahoo.com - March 28 at 9:12 AMTrillium House, an affordable housing project in Warrenton, close to completiondailyastorian.com - January 10 at 12:26 AMFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinomanz.finance.yahoo.com - October 19 at 9:39 AMCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatmentseekingalpha.com - September 14 at 9:48 AMZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directorsnz.finance.yahoo.com - September 12 at 7:55 AMPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Neededseekingalpha.com - August 17 at 11:07 AMTTI reviews parking modelchronicle.co.zw - August 10 at 10:41 PMTTI working round the clock to configure its systemschronicle.co.zw - August 10 at 10:41 PMPfizer in advanced talks to buy firm making sickle cell drugspmnewsnigeria.com - August 7 at 3:57 AM10 Psychedelics CEOs To Pay Attention To In 2022markets.businessinsider.com - June 22 at 10:08 AMHighlights from ASCO Annual Meeting 2022healio.com - June 15 at 1:37 PMChlormethine gel may be more effective than ointment for mycosis fungoideshealio.com - May 27 at 4:34 PMPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?edition.cnn.com - May 20 at 2:06 PMMedia Sentiment Over TimeCompany DescriptionsAdvisorShares Q Portfolio Blended Allocation ETFNYSEARCA:QPTTrillium TherapeuticsNASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
